Receptor Discordance During the Treatment Course of Patients With Metastatic Breast Cancer: Results From the SONABRE Registry
Clinical Breast Cancer · 2025
DOI: 10.1016/j.clbc.2025.07.020 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Breast Cancer, 2025. Verfasst von Karlijn E P E Hermans und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, GROW, Maastricht University Medical Center, Maastricht, The Netherlands. Electronic address: karlijn.hermans@mumc.nl. Hauptthemen laut MEDLINE: Breast Neoplasms, Receptors, Estrogen, Erb-b2 Receptor Tyrosine Kinases, Receptors, Progesterone. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences, AstraZeneca PLC.
Abstract (Originalsprache)
PURPOSE: The aim was to evaluate factors associated with taking 2 biopsies during the disease course of metastatic breast cancer (mBC) and to assess discordance rates for the oestrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). METHODS: Patients diagnosed with mBC in ten Dutch hospitals between 2007 and 2020 were retrieved from the SONABRE Registry (NCT-03577197). Patients were identified if they had at least 2 biopsies at different time points during their mBC disease course. Last follow-up was collected in September 2023. Frequencies and factors related to a second biopsy were studied using competing risk analysis with subdistribution hazard ratios (sHR). Discordance rates and factors associated with receptor subtype discordance were analysed using logistic regression using odds ratios (OR). RESULTS: Of 4,470 patients with mBC, 65% had 1 and 10% 2 biopsies during the course of mBC. Having 2 biopsies for mBC was related to age (sHR: 0.61), comorbidity (sHR: 0.76), WHO performance score (sHR: 0.30 for ≥2), initial TN subtype (sHR: 0.67), and initial metastatic site (sHR: 3.68 for soft tissue only), compared with the reference categories. Patients had an overall receptor subtype discordance of 23% compared to the second biopsy. Only HR+/HER2+ status was related to receptor subtype discordance (OR: 6.45). CONCLUSION: Only the minority of patients with mBC underwent a second biopsy during their mBC disease course. Receptor subtype heterogeneity is however frequent, particularly in patients with initially HR+/HER2+ mBC. Future studies are needed to guide treatment decisions as heterogeneity may play a role.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, GROW, Maastricht University Medical Center, Maastricht, The Netherlands. Electronic address: karlijn.hermans@mumc.nl.
- Department of Medical Oncology, GROW, Maastricht University Medical Center, Maastricht, The Netherlands.
- Department of Medical Oncology, Zuyderland Medical Center, Sittard/Heerlen, The Netherlands.
- Department of Medical Oncology, Jeroen Bosch Hospital, Den Bosch, The Netherlands.
- Department of Medical Oncology, Amphia, Breda, The Netherlands.
- Department of Medical Oncology, Máxima Medical Center, Veldhoven/Eindhoven, The Netherlands.
Förderung
- Gilead Sciences
- AstraZeneca PLC
Zitieren
APA
Hermans, K. E. P. E., Geurts, S. M. E., Van den Berkmortel, F., Tol, J., Heijns, J. B., Dercksen, M. W., Vriens, B. E. P. J., Aaldering, K. N. A., Pepels, M. J. A. E., Peters, N. A. J. B., van de Winkel, L., Boon, E., Teeuwen, N., van Kats, M. A. C. E., & Tjan-Heijnen, V. C. G. (2025). Receptor Discordance During the Treatment Course of Patients With Metastatic Breast Cancer: Results From the SONABRE Registry. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2025.07.020
Vancouver
Hermans KEPE, Geurts SME, Van den Berkmortel F, Tol J, Heijns JB, Dercksen MW, et al. Receptor Discordance During the Treatment Course of Patients With Metastatic Breast Cancer: Results From the SONABRE Registry. Clinical Breast Cancer. 2025. doi:10.1016/j.clbc.2025.07.020
BibTeX
@article{Hermans2025,
author = {Hermans, Karlijn E P E and Geurts, Sandra M E and Van den Berkmortel, Franchette and Tol, Jolien and Heijns, Joan B and Dercksen, Marcus W and Vriens, Birgit E P J and Aaldering, Kirsten N A and Pepels, Manon J A E and Peters, Natascha A J B and van de Winkel, Linda and Boon, Eline and Teeuwen, Nathalie and van Kats, Maartje A C E and Tjan-Heijnen, Vivianne C G},
title = {Receptor Discordance During the Treatment Course of Patients With Metastatic Breast Cancer: Results From the SONABRE Registry},
journal = {Clinical Breast Cancer},
year = {2025},
doi = {10.1016/j.clbc.2025.07.020}
}
EUVIMED